Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Burning away bile duct blockages: a new weapon against cholangiocarcinoma?

NCT ID NCT06175845

Disease control Sponsor: Universitätsklinikum Hamburg-Eppendorf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

This trial tests whether adding radiofrequency ablation to standard chemotherapy and bile duct stenting helps patients with inoperable bile duct cancer. Radiofrequency ablation uses a catheter to deliver heat that destroys tumor tissue blocking the bile duct. Researchers compare two groups: one receives the added ablation, the other does not. They track how long it takes for stents to fail, whether chemotherapy gets delayed, and overall safety and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency ablation of the bile duct using a catheter
What this could lead to
If it works, adding radiofrequency ablation to standard chemotherapy and stenting could help patients with inoperable bile duct cancer avoid stent blockages and treatment delays.
What could go wrong
This is an early study in a hard-to-treat cancer, and burning tumor tissue inside bile ducts can cause bleeding, infection, or damage to nearby structures. The approach may not extend survival or may help only some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Unresectable perihilar and/or ductal CCA with bile duct stenting and palliative systemic therapy as indicated by the local Multidisciplinary Team (MDT) 2. Written informed consent 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 4. Age ≥18 years 5. Eligibility for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT 6. No prior radiofrequency ablation (RFA) for CCA 7. No repeated bile duct stenting in the past 3 months (trial inclusion is possible upon first stent replacement or initial stent placement within past 3 months) 8. No concomitant disease or malignancy interfering with the study procedure or efficacy outcome measures, particularly no severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, myocardial infarction within ≤3 months, significant arrhythmias) and no psychiatric disorders precluding understanding of information of trial related topics and giving informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bile duct cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bile duct cancer bile duct neoplasm Bites and Stings cholangiocarcinoma cholangitis hilar cholangiocarcinoma liver cancer Liver Neoplasms perihilar intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bile duct cancer Cholangiocarcinoma Klatskin tumor Liver cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charite

    RECRUITING

    Berlin, Germany

  • Clinic Chemnitz

    RECRUITING

    Chemnitz, Germany

  • Clinic Ulm

    RECRUITING

    Ulm, Germany

  • Medical School Hannover

    RECRUITING

    Hanover, Germany

  • UKSH

    RECRUITING

    Lübeck, Germany

  • University Clinic

    RECRUITING

    Essen, Germany

  • University Clinic

    RECRUITING

    Heidelberg, Germany

  • University Medical Center

    RECRUITING

    Bonn, Germany

  • University Medical Center Hamburg-Eppendorf

    RECRUITING

    Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.